Review
Dermatology
Silvia Mariel Ferrucci, Simona Tavecchio, Angelo Valerio Marzano, Stefano Buffon
Summary: Atopic dermatitis (AD) is a chronic inflammatory skin disease caused by the interaction between environmental factors and genetically predisposed individuals. AD significantly impacts the patient's quality of life and well-being. Classical treatment options include topical corticosteroids, calcineurin inhibitors, phototherapy, and systemic immunosuppression. The development of dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, has revolutionized the treatment of moderate-to-severe or severe AD.
DERMATOLOGY AND THERAPY
(2023)
Review
Allergy
Doreen Siegels, Annice Heratizadeh, Susanne Abraham, Jonas Binnmyr, Knut Brockow, Alan D. Irvine, Susanne Halken, Charlotte G. Mortz, Carsten Flohr, Peter Schmid-Grendelmeier, Lauri-Ann Van der Poel, Antonella Muraro, Stephan Weidinger, Thomas Werfel, Jochen Schmitt
Summary: This study critically evaluated systemic treatments for moderate-to-severe AD, with the most reliable and safe trial evidence found for the use of dupilumab in adults for up to 1 year. Limited evidence-based conclusions were drawn for other systemic treatments due to methodological restrictions. Therefore, head-to-head trials with novel systemic treatments are needed to clarify the future role of conventional therapies.
Letter
Medicine, General & Internal
Brandon I. Smith, Priya Engel, Jashin Wu
Summary: The authors conclude that lebrikizumab therapy is safe and effective for moderate-to-severe atopic dermatitis in adolescents and adults based on two phase 3 trials. However, they note the lack of racial diversity in the trials, with majority of the patients being White.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Dermatology
Giovanni Paolino, Matteo Riccardo Di Nicola, Pina Brianti, Vittoria Giulia Bianchi, Santo Raffaele Mercuri
Summary: Atopic dermatitis and psoriasis are not mutually exclusive diseases, as they may coexist or develop subsequently in the same patient. Clinicians should carefully evaluate any changes in these patients in order to make a correct diagnosis and provide appropriate treatment.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Raj Chovatiya, Jonathan I. Silverberg
Summary: DESCRIBE-AD is a novel framework that standardizes the assessment of atopic dermatitis (AD), capturing multiple factors such as morphology, disease progression, symptom severity, comorbidities, treatment response, lesion intensity, disease burden, and lesion extent. It provides a comprehensive approach to describe the heterogeneity of AD and guide treatment decisions.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Review
Medicine, General & Internal
Youna Rodriguez-Le Roy, Anne-Sophie Ficheux, Laurent Misery, Emilie Brenaut
Summary: This study reviewed the literature on the effects of AD treatments on pruritus and conducted a meta-analysis. The results showed that most treatments had a positive effect on pruritus, but the degree of improvement varied among different treatments.
FRONTIERS IN MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Yoshie Umehara, Chanisa Kiatsurayanon, Juan Valentin Trujillo-Paez, Panjit Chieosilapatham, Ge Peng, Hainan Yue, Hai Le Thanh Nguyen, Pu Song, Ko Okumura, Hideoki Ogawa, Francois Niyonsaba
Summary: Itch or pruritus is a hallmark of atopic dermatitis and is believed to be a signal of danger from various environmental factors or physiological abnormalities. While histamine is a well-known substance inducing itch, H-1-antihistamines may not be fully effective against intractable itch in patients with atopic dermatitis. Treatment of the underlying conditions that cause itch is necessary to improve the quality of life of patients with atopic dermatitis.
Review
Allergy
Alexandra Paolino, Helen Alexander, Conor Broderick, Carsten Flohr
Summary: Atopic dermatitis is a common inflammatory skin condition that has an unpredictable course and significant impact on quality of life. Its pathophysiology involves impaired skin barrier function, immune dysregulation, genetic susceptibility, and environmental factors. Advances in understanding the immunological mechanisms of atopic dermatitis have led to the identification of novel therapeutic targets for systemic treatment. This review discusses current and future directions of non-biologic systemic treatments, including their mechanism of action, efficacy, safety, and important considerations for treatment decisions. It also highlights new developments in small molecule systemic therapies that have the potential to advance the management of atopic dermatitis in the era of precision medicine.
CLINICAL AND EXPERIMENTAL ALLERGY
(2023)
Article
Dermatology
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, G. Avila Valle, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara Pinton, S. Christen-Zach, M. Deleuran, M. Dittmann, C. Dressler, A. H. Fink-Wagner, N. Fosse, K. Gaspar, L. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, C. G. Mortz, A. Nast, U. Nygaard, M. Redding, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra-Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, C. Flohr
Summary: The evidence- and consensus-based guideline on atopic eczema, developed according to the EuroGuiDerm Guideline and Consensus Statement Development Manual, involves the participation of 29 experts from 12 European countries. The first part of the guideline provides general information, guidance, and detailed information on systemic treatment options, including conventional immunosuppressive drugs, biologics, and janus kinase inhibitors. The second part will cover other aspects of treatment.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Dermatology
Jose Manuel Carrascosa Carrillo, Eulalia Baselga Torres, Yolanda Gilaberte Calzada, Yanina Nancy Jurgens Martinez, Gaston Roustan Gullon, Juan Ignacio Yanguas Bayona, Susana Gomez Castro, Maria Giovanna Ferrario, Francisco Jose Rebollo Laserna
Summary: This study explores physician preferences in the systemic treatment of moderate-to-severe AD and identifies the factors that influence their choice of treatment. The results show that objective clinical efficacy and risk of severe adverse events (AEs) are considered the most important attributes, followed by improvement in sleep and pruritus and faster onset of action from the start of treatment. Physicians are willing to accept increased risks of AEs in order to obtain improvements in efficacy, sleep, and pruritus.
DERMATOLOGY AND THERAPY
(2022)
Review
Dermatology
Norito Katoh
Summary: Research on the pathophysiology of atopic dermatitis has led to the development of new pharmacological agents, such as biologics targeting cytokines, which are expected to be effective in patients refractory to conventional treatments. The use of predictive biomarkers for each drug is anticipated to optimize treatment, and tools to support patient self-decision-making may increase treatment satisfaction and adherence.
JOURNAL OF DERMATOLOGY
(2021)
Review
Dermatology
Kyohei Miyano, Yuichiro Tsunemi
Summary: The goal of treating atopic dermatitis is to achieve and maintain mild symptoms or symptom-free state. Topical therapy is the basis, but systemic therapies like dupilumab are needed for moderate to severe cases, offering high efficacy and fewer adverse reactions.
JOURNAL OF DERMATOLOGY
(2021)
Article
Medicine, General & Internal
Sebastian Kiefer, Anke Koenig, Viviane Gerger, Christine Rummenigge, Anne Christine Mueller, Thomas Jung, Alexandra Frank, Georgios Tassopoulos, Emilie Laurent, Roland Kaufmann, Andreas Pinter
Summary: This study investigated the efficacy, safety, and treatment satisfaction of dupilumab and upadacitinib in 23 pediatric patients with moderate-to-severe atopic dermatitis. Both drugs showed significant improvement in the patients' skin condition and symptom relief, with no significant difference observed between the two options.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Dermatology
Sheridan M. Hoy
Summary: Baricitinib is an oral alternative for the treatment of moderate to severe atopic dermatitis in adults. It provides significant and rapid improvements in disease severity and quality of life, making it a potential option for patients who are candidates for systemic therapy.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2022)
Review
Pediatrics
Jennifer B. Scott, Amy S. Paller
Summary: New and emerging therapies for pediatric atopic dermatitis have been developed based on recent research highlighting the importance of type 2 immunity and the interplay between the skin immune system, epidermal barrier, and microbiome in the pathogenesis of the disease. These therapies include both topical and systemic agents, offering more targeted treatment options for a broader range of children and adolescents with moderate-to-severe atopic dermatitis.
CURRENT OPINION IN PEDIATRICS
(2021)
Letter
Dermatology
Jonathan I. Silverberg, Stephanie M. Rangel, Anjani Sheth, Alli Blumstein, Amy S. Paller
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Allergy
Jonathan I. Silverberg, Manotri Chaubal, Erin M. Warshaw, Howard I. Maibach, Donald V. Belsito, Joel G. DeKoven, Kathryn A. Zug, James S. Taylor, Denis Sasseville, Vincent A. DeLeo, Melanie D. Pratt, Margo J. Reeder, Amber R. Atwater, Joseph F. Fowler Jr, Marie-Claude Houle
Summary: This study retrospectively analyzed the clinical characteristics and allergen relevance in patients with cheilitis referred for patch testing. The study found that the prevalence of cheilitis has been increasing over the years, and patients with cheilitis had a high rate of positive reactions to allergens.
CONTACT DERMATITIS
(2023)
Article
Dermatology
Jonathan I. Silverberg, Jennifer A. Mohawk, Joshua Cirulli, Kristine Nograles, Joseph C. Punzalan, Kevin M. Kelly, Brian S. Kim, Emma Guttman-Yassky, Mark Lebwohl
Summary: In adults with atopic dermatitis (AD), the severity of symptoms and treatment success vary. Itch is the most bothersome symptom, and topical therapies result in low treatment satisfaction. Therefore, there is a need for systemic antipruritic therapies to reduce itch in AD patients.
Article
Dermatology
Jaya Manjunath, Donald Lei, Adnan Ahmed, Marissa Ayasse, Rajeev Chavda, Sylvie Gabriel, Jonathan Ian Silverberg
Summary: This study investigated sleep disturbance in patients with atopic dermatitis (AD) and found that a significant proportion of patients with moderate-to-severe AD and frequent itch experienced sleep disturbance. Although sleep quality improved over time, some patients had fluctuating or persistent sleep disturbance.
Article
Dermatology
Jonathan I. Silverberg, Eric L. Simpson, Jacob Pontoppidan Thyssen, Thomas Werfel, Tracy E. Cardillo, Stephanie Colvin, Evangeline Pierce, Yun-Fei Chen, Sherry Chen, Lawrence Eichenfield
Summary: Baricitinib combined with topical corticosteroids (TCS) has shown sustained efficacy in treating adults with moderate-to-severe atopic dermatitis (AD) over a 68-week period.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Jonathan I. Silverberg, Robert Bissonnette, Leon Kircik, Dedee F. Murrell, Andrew Selfridge, Kris Liu, Gurpreet Ahluwalia, Emma Guttman-Yassky
Summary: This study evaluated the efficacy and safety of etrasimod monotherapy in the treatment of moderate-to-severe atopic dermatitis. The results showed that etrasimod 2 mg demonstrated efficacy on clinician- and patient-assessed measures, and both 1 mg and 2 mg doses were well tolerated, supporting further clinical investigation in atopic dermatitis.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Stephanie M. Rangel, Theodore Kim, Anjani Sheth, Alli Blumstein, Jin-Shei Lai, David Cella, Amy S. Paller, Jonathan Silverberg
Summary: This study aims to determine the prevalence of fatigue in AD patients, and whether AD severity, demographics and comorbidities are associated with increased fatigue in children. The results showed that many children with AD had no or mild fatigue, but fatigue was associated with AD severity, history of allergic diseases, and family income.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Medicine, General & Internal
Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaci, Alan D. Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L. Simpson, Chia-Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar G. Pillai, Julien Seneschal
Summary: Two 52-week trials showed that treatment with lebrikizumab was effective in improving skin condition and reducing itch severity in patients with moderate-to-severe atopic dermatitis. The incidence of adverse events was generally mild to moderate and did not lead to trial discontinuation.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Dermatology
Meredith Tyree Polaskey, Anne Bendelow, Janak Mukherji, Brooke Buranosky, Jonathan I. Silverberg, Anna Fishbein
Summary: Early childhood atopic dermatitis often precedes food sensitization and allergy, but the effect of treating atopic dermatitis on preventing food allergy is still unclear. We aimed to evaluate the relationship between facial dermatitis and food sensitization to cow's milk, egg whites, and peanuts in early childhood, as aggressive treatment of facial dermatitis could potentially help prevent food sensitization. By the age of 3, children with facial atopic dermatitis had a 48% higher level of food sensitization to cow's milk, egg whites, and peanuts compared to those without facial involvement. Further research is needed to determine if facial involvement of atopic dermatitis is associated with increased food allergy.
PEDIATRIC DERMATOLOGY
(2023)
Article
Medicine, General & Internal
Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaci, Alan D. Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L. Simpson, Chia-Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar G. Pillai, Julien Seneschal
Summary: The study shows that lebrikizumab is effective in treating moderate-to-severe atopic dermatitis in both adolescents and adults, with significant improvements in skin lesions and reduction of itch symptoms during the 16-week induction period.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Dermatology
Ladonya Jackson-Cowan, Jonathan I. Silverberg
Summary: Recent study showed that cognitive impairment is related to pruritus in patients with atopic dermatitis (AD). In this longitudinal study, 20.85% of AD patients had impaired cognitive function. Among them, 34.09% had persistent impairment, 47.72% had fluctuating course, and 18.18% showed sustained improvement.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)
Article
Dermatology
Sneha Iyer, Nisha Patel, Eric Sanfilippo, Robert P. Dellavalle, Jonathan I. Silverberg
Summary: Little is known about the validity of ICD-10-CM codes for atopic dermatitis (AD) in healthcare claims databases. The study assessed the validity of ICD-10-CM codes for identifying adult patients with AD using a healthcare claims database. The results showed that the PPV of the ICD-10 codes alone for AD was poor, but combining the codes with comorbid atopic diseases improved the PPV and specificity at the expense of sensitivity.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)
Letter
Dermatology
Sarah J. Shareef, Rafey Rehman, Mahfujul Z. Haque, Jonathan I. Silverberg
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)
Article
Dermatology
Shanthi Narla, Candrice R. Heath, Andrew Alexis, Jonathan I. Silverberg
Summary: Significant racial/ethnic disparities in dermatologic care and their subsequent impact on dermatologic conditions were reported. Key contributing factors include socioeconomic factors, gaps in educational exposure, and underrepresentation of minority groups in the dermatologic workforce. The American Academy of Dermatology (AAD) announced a three-year plan to promote diversity, equity, and inclusion in dermatology. To reduce disparities, every dermatologist should receive adequate education in diseases, treatments, health equity, and culturally sensitive care. A diverse dermatologic workforce can improve cross-cultural understanding and treatment approaches for different racial/ethnic populations, while acknowledging and educating on the health impacts of racism is essential for the healthcare community.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)
Review
Dermatology
Alex M. Rokni, Marissa Ayasse, Adnan Ahmed, Lauren Guggina, Robert W. Kantor, Jonathan Silverberg
Summary: This study systematically reviewed the relationship between autoimmune blistering disease (AIBD) and cardiovascular disease (CVD) and its risk factors. The findings showed that AIBD was associated with diabetes, hypertension, dyslipidemia, and heart failure, but not with obesity, stroke, angina, heart attack, or arrhythmia. The study also found that treatment for AIBD could result in CVD-related adverse events.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)